ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1880

Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

Avneek Singh Sandhu1, Reto Kurmann2, Cynthia S. Crowson3, Rekha Mankad2, Eric L. Matteson4, Thomas Osborn1, Kenneth J. Warrington5 and Ashima Makol1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease, Diabetes, obesity and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Cardiac involvement, due to impairment of coronary microcirculation and myocardial fibrosis, affects prognosis in individuals with SSc, and represents one of the leading causes of death in this population. There is limited data on the risk of atherosclerotic cardiovascular disease (CVD) in SSc. We aimed to compare the prevalence of traditional CVD risk factors and incidence of atherosclerotic CVD events among incident cases of SSc vs age- and sex-matched comparators.

Methods: Medical records of patients with a diagnosis or suspicion of SSc in a geographically well-defined area from Jan 1, 1980 to Dec 31, 2016 were reviewed to identify incident cases of physician diagnosed SSc. Fulfillment of the 1980 and 2013 SSc classification criteria was ascertained. A 2:1 cohort of age- and sex-matched non-SSc subjects from the same population base was randomly selected for comparison. Data on SSc characteristics, traditional CVD risk factors (i.e., smoking status, obesity, hypertension, dyslipidemia, diabetes mellitus [DM]), and CVD events (i.e., coronary artery disease [CAD], peripheral artery disease [PAD], abdominal aortic aneurysm [AAA], cerebrovascular disease [stroke/TIA], and heart failure) were collected. Cumulative incidence was adjusted for the competing risk of death.

Results: The cohort included 79 incident SSc cases and 158 non-SSc comparators (mean age of 56 ± 16 years at diagnosis/index, 90% female for both cohorts; 87% [SSc] and 93% [non-SSc] Caucasian). Mean body mass index was significantly lower in SSc (26.5 ± 5.9 kg/m2) than non-SSc (29.3 ± 8.1 kg/m2; p=0.01). Diabetes mellitus was also less common in SSc than non-SSc at diagnosis/index (3% vs 9%, p=0.05). There were no differences in smoking, hypertension or hyperlipidemia. Prior to SSc diagnosis/index, there was no difference in the prevalence of any CVD events (15 SSc vs 19 non-SSc; p=0.17). During the median follow up of 9.8 y (SSc) and 8.9 y (non-SSc), 19 SSc and 15 non-SSc patients developed CVD events, for a 10-year cumulative incidence of 22.4% among SSc and 10.6% among non-SSc. This corresponded to a 3 fold increased risk (hazard ratio [HR]: 3.25; 95% confidence interval [CI]: 1.64-6.46, p=0.001) in SSc patients vs. comparators. This increased risk was predominately due to CAD (HR: 3.20; 95% CI: 1.56-6.72, p=0.002), but PAD/AAA risk also approached significance (HR: 4.20; 95% CI: 0.99-17.91, P=0.052). There was no evidence of increased risk of cerebrovascular events (HR: 1.06; 95% CI: 0.23-4.94, p=0.94).

Conclusion: Patients with incident SSc have a lower BMI and prevalence of DM than non-SSc comparators. Despite having no significant difference in the prevalence of traditional CVD risk factors and CVD events at baseline, patients with SSc have a >3 fold increase of CVD events after SSc diagnosis when compared to non-SSc comparators, predominately due to CAD. This increased rate warrants a high vigilance for CAD in patients with SSc. It may potentially be related to the increased risk of endothelial dysfunction, microvascular injury and chronic inflammation characteristic of the disease, but warrants further detailed study.


Disclosure: A. S. Sandhu, None; R. Kurmann, None; C. S. Crowson, None; R. Mankad, None; E. L. Matteson, None; T. Osborn, None; K. J. Warrington, None; A. Makol, None.

To cite this abstract in AMA style:

Sandhu AS, Kurmann R, Crowson CS, Mankad R, Matteson EL, Osborn T, Warrington KJ, Makol A. Cardiovascular (CV) Risk Factors and Atherosclerotic CV Events Among Incident Cases of Systemic Sclerosis: Results from a Population Based Cohort (1980-2016) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/cardiovascular-cv-risk-factors-and-atherosclerotic-cv-events-among-incident-cases-of-systemic-sclerosis-results-from-a-population-based-cohort-1980-2016/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-cv-risk-factors-and-atherosclerotic-cv-events-among-incident-cases-of-systemic-sclerosis-results-from-a-population-based-cohort-1980-2016/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology